Tamás Pinter1, Zandra Klippel2, Alvydas Cesas3, Adina Croitoru4, Jochen Decaestecker5, Peter Gibbs6, Yevhen Hotko7, Jacek Jassem8, Galina Kurteva9, Jan Novotny10, Seamus O'Reilly11, Tomas Salek12, Maureen Reiner13, Phuong Khanh Morrow2, Mi Rim Choi2, Sadie Whittaker2, Charles Blanke14. 1. Department of Oncoradiology, Petz Aladár Teaching Hospital, Györ, Hungary. Electronic address: pinterbely@gmail.com. 2. Clinical Development, Amgen Inc, Thousand Oaks, CA. 3. Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania. 4. Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania. 5. Department of Oncology, AZ Delta Hospital, Roeselare, Belgium. 6. Department of Oncology, The Western Hospital, Footscray, Victoria, Australia. 7. Uzhgorod Regional Oncology Dispensary, Uzhgorod National University, Uzhgorod, Ukraine. 8. Department of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland. 9. Clinic of Medical Oncology, Specialized Hospital for Active Treatment in Oncology Sofia, Sofia, Bulgaria. 10. Department of Oncology, Institute of Oncology and Rehabilitation, Nová Ves pod Pleší, Czech Republic. 11. Department of Medical Oncology, Ireland Cooperative Oncology Research Group, Dublin, Ireland. 12. Department of Clinical Oncology, National Cancer Institute, Bratislava, Slovakia. 13. Global Biostatistical Sciences, Amgen Inc, Thousand Oaks, CA. 14. Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR.
Abstract
BACKGROUND:Pegfilgrastim's role in reducing the risk of febrile neutropenia (FN) in patients with colorectal cancer (CRC) receivingchemotherapy plus bevacizumab was not previously evaluated in a prospective study. The present phase III, double-blind trial evaluated the efficacy of pegfilgrastim versus placebo in reducing the incidence of grade 3/4 FN in patients with advanced CRC receivingbevacizumab combined with first-line chemotherapy (FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin] or FOLFIRI [leucovorin, 5-fluorouracil, irinotecan]). PATIENTS AND METHODS: Patients aged ≥ 18 years with locally advanced or metastatic CRC were randomized 1:1 to placebo or 6 mg of pegfilgrastim ∼24 hours after receiving chemotherapy plus bevacizumab every 14 days. The study treatment period included 4 cycles, but patients could continue treatment for ≤ 60 months. The primary endpoint was incidence of grade 3/4 FN in the first 4 cycles. The secondary endpoints included the objective response rate (ORR), overall survival, and progression-free survival, analyzed at the end of the long-term follow-up period. RESULTS: A total of 845 patients were randomized from November 2009 to January 2012 (422, pegfilgrastim; 423, placebo). Pegfilgrastim significantly reduced the incidence of grade 3/4 FN in the first 4 treatment cycles (pegfilgrastim, 2.4%; 95% confidence interval [CI], 1.1%-4.3%; placebo, 5.7%; 95% CI, 3.7%-8.3%; odds ratio [OR], 0.41; P = .014). No significant differences were observed between the 2 arms in ORR (OR, 1.15; P = .330), overall survival (hazard ratio, 0.94; P = .440), and progression-free survival (hazard ratio, 0.93; P = .300). CONCLUSION:Pegfilgrastim reduced the FN incidence in patients with advanced CRC receiving chemotherapy andbevacizumab. Administration of pegfilgrastim was tolerable and did not negatively affect the tumor response or survival in this patient population.
RCT Entities:
BACKGROUND: Pegfilgrastim's role in reducing the risk of febrile neutropenia (FN) in patients with colorectal cancer (CRC) receiving chemotherapy plus bevacizumab was not previously evaluated in a prospective study. The present phase III, double-blind trial evaluated the efficacy of pegfilgrastim versus placebo in reducing the incidence of grade 3/4 FN in patients with advanced CRC receiving bevacizumab combined with first-line chemotherapy (FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin] or FOLFIRI [leucovorin, 5-fluorouracil, irinotecan]). PATIENTS AND METHODS: Patients aged ≥ 18 years with locally advanced or metastatic CRC were randomized 1:1 to placebo or 6 mg of pegfilgrastim ∼24 hours after receiving chemotherapy plus bevacizumab every 14 days. The study treatment period included 4 cycles, but patients could continue treatment for ≤ 60 months. The primary endpoint was incidence of grade 3/4 FN in the first 4 cycles. The secondary endpoints included the objective response rate (ORR), overall survival, and progression-free survival, analyzed at the end of the long-term follow-up period. RESULTS: A total of 845 patients were randomized from November 2009 to January 2012 (422, pegfilgrastim; 423, placebo). Pegfilgrastim significantly reduced the incidence of grade 3/4 FN in the first 4 treatment cycles (pegfilgrastim, 2.4%; 95% confidence interval [CI], 1.1%-4.3%; placebo, 5.7%; 95% CI, 3.7%-8.3%; odds ratio [OR], 0.41; P = .014). No significant differences were observed between the 2 arms in ORR (OR, 1.15; P = .330), overall survival (hazard ratio, 0.94; P = .440), and progression-free survival (hazard ratio, 0.93; P = .300). CONCLUSION: Pegfilgrastim reduced the FN incidence in patients with advanced CRC receiving chemotherapy and bevacizumab. Administration of pegfilgrastim was tolerable and did not negatively affect the tumor response or survival in this patient population.